MedPath

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Completed
Conditions
oncologische aandoeningen
cancer
advanced cancer
Registration Number
NL-OMON52263
Lead Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
156
Inclusion Criteria

The study population will consist of patients with advanced solid organ cancer
(except brain cancer) and their primary family caregiver.

Inclusion criteria
Patient
Diagnosis of cancer: solid organ (lung, colorectal, breast, prostate and other)
No longer receives curative treatment (only life-prolonging or palliative
treatments)
Written informed consent
Lives within 100 km for intervention nurses to travel
Family caregiver
Written informed consent
Primary informal caregiver as determined by the patient
Lives within 100 km for intervention nurses to travel
Dyad
Patient and/or family caregivers has access to and is familiar with use of
internet

Exclusion Criteria

Exclusion criteria
Brain cancer, brain metastases, non-solid cancers
Prognosis of less than 3 months
Has no informal caregivers
< 18 years old
Unable to participate in available languages
Family caregiver
Unable to physically or mentally participate
Cancer diagnosis in the last 12 months
<18 years old
Unable to participate in available languages

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The primary endpoints are emotional functioning and self-efficacy of both the<br /><br>person with advanced cancer and the family caregiver at t1.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>The secondary endpoints are: quality of life of the patient and caregiver,<br /><br>benefits of illness, coping, dyadic communication, ways of giving support at<br /><br>t1. All listed primary and secondary outcomes at t2 and formal healthcare use<br /><br>and costs at t1 and t2</p><br>
© Copyright 2025. All Rights Reserved by MedPath